留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

Musashi-2在恶性肿瘤发生发展及诊疗靶点中的作用

张苏杰 殷华奇 叶雄俊 徐涛

张苏杰, 殷华奇, 叶雄俊, 徐涛. Musashi-2在恶性肿瘤发生发展及诊疗靶点中的作用[J]. 协和医学杂志, 2017, 8(4-5): 289-293. doi: 10.3969/j.issn.1674-9081.2017.05.018
引用本文: 张苏杰, 殷华奇, 叶雄俊, 徐涛. Musashi-2在恶性肿瘤发生发展及诊疗靶点中的作用[J]. 协和医学杂志, 2017, 8(4-5): 289-293. doi: 10.3969/j.issn.1674-9081.2017.05.018
Su-jie ZHANG, Hua-qi YIN, Xiong-jun YE, Tao XU. Role of Musashi-2 in the Occurrence and Development and as the Diagnostic and Therapeutic Target of Malignant Tumors[J]. Medical Journal of Peking Union Medical College Hospital, 2017, 8(4-5): 289-293. doi: 10.3969/j.issn.1674-9081.2017.05.018
Citation: Su-jie ZHANG, Hua-qi YIN, Xiong-jun YE, Tao XU. Role of Musashi-2 in the Occurrence and Development and as the Diagnostic and Therapeutic Target of Malignant Tumors[J]. Medical Journal of Peking Union Medical College Hospital, 2017, 8(4-5): 289-293. doi: 10.3969/j.issn.1674-9081.2017.05.018

Musashi-2在恶性肿瘤发生发展及诊疗靶点中的作用

doi: 10.3969/j.issn.1674-9081.2017.05.018
详细信息
    通讯作者:

    徐涛  电话:010-88325911, E-mail: xutao@medmail.com.cn

  • 中图分类号: [R394.3];R73

Role of Musashi-2 in the Occurrence and Development and as the Diagnostic and Therapeutic Target of Malignant Tumors

More Information
  • 摘要: Musashi-2(Msi-2)蛋白自发现以来, 有关其在干细胞未分化状态和自我更新能力中发挥的作用一直是研究的热点, 而近年来也证实Msi-2在恶性肿瘤的发生、发展中起到关键性作用, 现有研究不仅仅局限于Msi-2促进恶性肿瘤发生发展的机制, Msi-2应用于恶性肿瘤诊断和个体化治疗的价值也日益凸显。本文将对Msi-2在恶性肿瘤发生发展中的作用及其作为诊断及治疗靶点的最新研究进展进行综述。
  • [1] Okano H, Imai T, Okabe M. Musashi:a translational regulator of cell fate[J]. J Cell Sci, 2002, 115:1355-1359. http://europepmc.org/abstract/MED/11896183
    [2] Nakamura M, Okano H, Blendy JA, et al. Musashi, a neural RNA-binding protein required for Drosophila adult external sensory organ development[J]. Neuron, 1994, 13:67-81. doi:  10.1016/0896-6273(94)90460-X
    [3] Sakakibara S, Nakamura Y, Satoh H, et al. Rna-binding protein Musashi2:developmentally regulated expression in neural precursor cells and subpopulations of neurons in mammalian CNS[J]. J Neurosci, 2001, 21:8091-8107. doi:  10.1523/JNEUROSCI.21-20-08091.2001
    [4] Hope KJ, Cellot S, Ting SB, et al. An RNAi screen identifies Msi2 and Prox1 as having opposite roles in the regulation of hematopoietic stem cell activity[J]. Cell Stem Cell, 2010, 7:101-113. doi:  10.1016/j.stem.2010.06.007
    [5] Hattori E, Shu HJ, Saito T, et al. Expression of the RNA-binding protein Musashi1 in adult liver stem-like cells[J]. Hepatol Res, 2010, 40:432-437. doi:  10.1111/j.1872-034X.2009.00612.x
    [6] Samuel S, Walsh R, Webb J, et al. Characterization of putative stem cells in isolated human colonic crypt epithelial cells and their interactions with myofibroblasts[J]. Am J Physiol Cell Physiol, 2009, 296:C296-C305. doi:  10.1152/ajpcell.00383.2008
    [7] Clarke RB, Spence K, Anderson E, et al. A putative human breast stem cell population is enriched for steroid receptor-positive cells[J]. Dev Biol, 2005, 277:443-456. doi:  10.1016/j.ydbio.2004.07.044
    [8] Han SP, Tang YH, Smith R. Functional diversity of the hnRNPs:past, present and perspectives[J]. Biochem J, 2010, 430:379-392. doi:  10.1042/BJ20100396
    [9] Barbouti A, Hoglund M, Johansson B, et al. A novel gene, MSI2, encoding a putative RNA-binding protein is recurrently rearranged at disease progression of chronic myeloid leukemia and forms a fusion gene with HOXA9 as a result of the cryptic t(7;17)(p15;q23)[J]. Cancer Res, 2003, 63:1202-1206. http://www.ncbi.nlm.nih.gov/pubmed/12649177
    [10] Sakakibara S, Nakamura Y, Yoshida T, et al. RNA-binding protein Musashi family:roles for CNS stem cells and a subpopulation of ependymal cells revealed by targeted disruption and antisense ablation[J]. Proc Natl Acad Sci USA, 2002, 99:15194-15199. doi:  10.1073/pnas.232087499
    [11] Ito T, Kwon HY, Zimdahl B, et al. Regulation of myeloid leukaemia by the cell-fate determinant Musashi[J]. Nature, 2010, 466:765-768. doi:  10.1038/nature09171
    [12] Kharas MG, Lengner CJ, Al-Shahrour F, et al. Musashi-2 regulates normal hematopoiesis and promotes aggressive myeloid leukemia[J]. Nat Med, 2010, 16:903-908. doi:  10.1038/nm.2187
    [13] Pattabiraman DR, Weinberg RA. Tackling the cancer stem cells-what challenges do they pose?[J]. Nat Rev Drug Discov, 2014, 13:497-512. doi:  10.1038/nrd4253
    [14] Wang S, Li N, Yousefi M, et al. Transformation of the intestinal epithelium by the MSI2 RNA-binding protein[J]. Nat Commun, 2015, 6:6517. doi:  10.1038/ncomms7517
    [15] Guo K, Cui J, Quan M, et al. The novel KLF4/MSI2 signaling pathway regulates growth and metastasis of pancreatic cancer[J]. Clin Cancer Res, 2017, 23:687-696. doi:  10.1158/1078-0432.CCR-16-1064
    [16] Choi YM, Kim KB, Lee JH, et al. DBC2/RhoBTB2 functions as a tumor suppressor protein via Musashi-2 ubiquitination in breast cancer[J]. Oncogene, 2017, 36:2802-2812. doi:  10.1038/onc.2016.441
    [17] Fujiwara T, Zhou J, Ye S, et al. RNA-binding protein Musashi2 induced by RANKL is critical for osteoclast survival[J]. Cell Death Dis, 2016, 7:e2300. doi:  10.1038/cddis.2016.213
    [18] Kwon HY, Bajaj J, Ito T, et al. Tetraspanin 3 is required for the development and propagation of acute myelogenous leukemia[J]. Cell Stem Cell, 2015, 17:152-164. doi:  10.1016/j.stem.2015.06.006
    [19] Kaeda J, Ringel F, Oberender C, et al. Longitudinal study to assess the clinical significance of MSI2 expression in chronic myeloid leukemia patients[J]. Acta Haematol, 2016, 136:62-64. doi:  10.1159/000445097
    [20] Park SM, Gonen M, Vu L, et al. Musashi2 sustains the mixed-lineage leukemia-driven stem cell regulatory program[J]. J Clin Invest, 2015, 125:1286-1298. doi:  10.1172/JCI78440
    [21] Byers RJ, Currie T, Tholouli E, et al. MSI2 protein expression predicts unfavorable outcome in acute myeloid leukemia[J]. Blood, 2011, 118:2857-2867. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=9aa977e6516404f5a67b1f2c43519a0c
    [22] Hattori A, Mcskimming D, Kannan N, et al. RNA binding protein MSI2 positively regulates FLT3 expression in myeloid leukemia[J]. Leuk Res, 2017, 54:47-54. doi:  10.1016/j.leukres.2017.01.015
    [23] Zhao HZ, Jia M, Luo ZB, et al. Prognostic significance of the Musashi-2(MSI2) gene in childhood acute lymphoblastic leukemia[J]. Neoplasma, 2016, 63:150-157. doi:  10.4149/neo_2016_018
    [24] Mu Q, Wang Y, Chen B, et al. High expression of Musashi-2 indicates poor prognosis in adult B-cell acute lymphoblastic leukemia[J]. Leuk Res, 2013, 37:922-927. doi:  10.1016/j.leukres.2013.05.012
    [25] Taggart J, Ho T C, Amin E, et al. MSI2 is required for maintaining activated myelodysplastic syndrome stem cells[J]. Nat Commun, 2016, 7:10739. doi:  10.1038/ncomms10739
    [26] He L, Zhou X, Qu C, et al. Musashi2 predicts poor prognosis and invasion in hepatocellular carcinoma by driving epithelial-mesenchymal transition[J]. J Cell Mol Med, 2014, 18:49-58. doi:  10.1111/jcmm.12158
    [27] Wang MH, Qin SY, Zhang SG, et al. Musashi-2 promotes hepatitis Bvirus related hepatocellular carcinoma progression via the Wnt/beta-catenin pathway[J]. Am J Cancer Res, 2015, 5:1089-1100. http://pubmedcentralcanada.ca/pmcc/articles/PMC4449437/
    [28] Li N, Yousefi M, Nakauka-Ddamba A, et al. The Msi Family of RNA-Binding Proteins Function Redundantly as Intestinal Oncoproteins[J]. Cell Rep, 2015, 13:2440-2455. doi:  10.1016/j.celrep.2015.11.022
    [29] Zong Z, Zhou T, Rao L, et al. Musashi2 as a novel predictive biomarker for liver metastasis and poor prognosis in colorectal cancer[J]. Cancer Med, 2016, 5:623-630. doi:  10.1002/cam4.624
    [30] Kudinov AE, Deneka A, Nikonova AS, et al. Musashi-2(MSI2) supports TGF-beta signaling and inhibits claudins to promote non-small cell lung cancer(NSCLC) metastasis[J]. Proc Natl Acad Sci U S A, 2016, 113:6955-6960. doi:  10.1073/pnas.1513616113
    [31] Katz Y, Li F, Lambert NJ, et al. Musashi proteins are post-transcriptional regulators of the epithelial-luminal cell state[J]. Elife, 2014, 3:e3915. http://www.ncbi.nlm.nih.gov/pubmed/25380226
    [32] Kang MH, Jeong KJ, Kim WY, et al. Musashi RNA-binding protein 2 regulates estrogen receptor 1 function in breast cancer[J]. Oncogene, 2017, 36:1745-1752. doi:  10.1038/onc.2016.327
    [33] Nahas GR, Murthy RG, Patel SA, et al. The RNA-binding protein Musashi 1 stabilizes the oncotachykinin 1 mRNA in breast cancer cells to promote cell growth[J]. FASEB J, 2016, 30:149-159. doi:  10.1096/fj.15-278770
    [34] Yang C, Zhang W, Wang L, et al. Musashi-2 promotes migration and invasion in bladder cancer via activation of the JAK2/STAT3 pathway[J]. Lab Invest, 2016, 96:950-958. doi:  10.1038/labinvest.2016.71
    [35] Cox JL, Wilder PJ, Gilmore JM, et al. The SOX2-interactome in brain cancer cells identifies the requirement of MSI2 and USP9X for the growth of brain tumor cells[J]. PLoS One, 2013, 8:e62857. doi:  10.1371/journal.pone.0062857
    [36] Emadi-Baygi M, Nikpour P, Mohammad-Hashem F, et al. MSI2 expression is decreased in grade II of gastric carcinoma[J]. Pathol Res Pract, 2013, 209:689-691. doi:  10.1016/j.prp.2013.07.008
    [37] Minuesa G, Antczak C, Shum D, et al. A 1536-well fluorescence polarization assay to screen for modulators of the MUSASHI family of RNA-binding proteins[J]. Comb Chem High Throughput Screen, 2014, 17:596-609. doi:  10.2174/1386207317666140609122714
    [38] Lan L, Appelman C, Smith AR, et al. Natural product(-)-gossypol inhibits colon cancer cell growth by targeting RNA-binding protein Musashi-1[J]. Mol Oncol, 2015, 9:1406-1420. doi:  10.1016/j.molonc.2015.03.014
    [39] Han Y, Ye A, Zhang Y, et al. Musashi-2 silencing exerts potent activity against acute myeloid leukemia and enhances chemosensitivity to daunorubicin[J]. PLoS One, 2015, 10:e136484. http://www.ncbi.nlm.nih.gov/pubmed/26308531
    [40] Lee J, An S, Choi YM, et al. Musashi-2 is a novel regulator of paclitaxel sensitivity in ovarian cancer cells[J]. Int J Oncol, 2016, 49:1945-1952. doi:  10.3892/ijo.2016.3683
  • 加载中
计量
  • 文章访问数:  14
  • HTML全文浏览量:  1
  • PDF下载量:  0
  • 被引次数: 0
出版历程
  • 收稿日期:  2017-06-24
  • 刊出日期:  2017-09-30

目录

    /

    返回文章
    返回

    【温馨提醒】近日,《协和医学杂志》编辑部接到作者反映,有多名不法人员冒充期刊编辑发送见刊通知,鼓动作者添加微信,从而骗取版面费的行为。特提醒您,本刊与作者联系的方式均为邮件通知或电话,稿件进度通知邮箱为:mjpumch@126.com,编辑部电话为:010-69154261,请提高警惕,谨防上当受骗!如有任何疑问,请致电编辑部核实。谢谢!